PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026
Published on 03/18/2026 at 11:05 | prnewswire.co.uk
If approved, imlifidase will be the first treatment to address highly sensitized patients awaiting kidney transplantation. View original content:https://www.prnewswire.co.uk/news-releases/pdufa-action-date-for-hansa-biopharmas-imlifidase-bla-set-for-december-19-2026-302704610.html
en | DE0007608606 | PDUFA | boerse | 68778775 |
